ArticleAnnals of hematology2026
Classical Hodgkin lymphoma associated with immune deficiency and dysregulation exhibits a prognosis similar to sporadic cases but with distinct predictive markers.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune deficiency and dysregulation (IDD)-associated classical Hodgkin lymphoma (cHL) is one of the common subtypes of IDD-related lymphomas. Patients with IDD-cHL are typically treated with the same chemotherapeutic regimens as those with sporadic cHL. However, the clinical differences between these groups remain poorly elucidated. To assess the impact of immune status on clinical features and treatment outcomes, 44 patients who were newly diagnosed with cHL and treated at our institution, including 12 with IDD-cHL, were retrospectively analyzed. Epstein-Barr virus-encoded small RNA positivity was significantly more common in patients with IDD-cHL than in those with sporadic cHL. Nevertheless, the baseline laboratory parameters did not significantly differ between the two groups. Patients with IDD-cHL had significantly higher rates of neutropenia than those with sporadic cHL, resulting in reduced relative dose intensity. However, the two groups were similar in terms of complete response and progression-free survival rates. Based on a prognostic analysis, serum lactate dehydrogenase (LDH) and soluble interleukin-2 receptor (sIL-2R) levels were associated with prognosis. However, their prognostic implications were contrasting in the two immune status groups. To integrate these markers, the prognostic value of the sIL-2R-to-LDH ratio (cutoff: 3.58) was evaluated. A higher ratio was significantly associated with poorer prognosis in sporadic cHL (p < 0.01). Meanwhile, in IDD-cHL, a lower ratio was associated with worse outcomes (p = 0.07). According to these findings, the overall clinical presentation of cHL and the efficacy of its treatment are significantly consistent regardless of immune status. However, the prognostic significance of specific biomarkers is distinct. The sIL-2R-to-LDH ratio may represent a broadly applicable prognostic marker, and its interpretation should be adapted according to the patient's immune background.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.